Richard Bernstein Advisors LLC Sells 2,449 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Richard Bernstein Advisors LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 65.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 1,321 shares of the biopharmaceutical company’s stock after selling 2,449 shares during the period. Richard Bernstein Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $743,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in REGN. Capital Research Global Investors raised its position in shares of Regeneron Pharmaceuticals by 3.6% in the third quarter. Capital Research Global Investors now owns 105,749 shares of the biopharmaceutical company’s stock valued at $59,455,000 after purchasing an additional 3,635 shares during the period. Capital World Investors boosted its holdings in Regeneron Pharmaceuticals by 1.6% in the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after buying an additional 32,348 shares during the period. Legal & General Group Plc boosted its holdings in Regeneron Pharmaceuticals by 4.2% in the 3rd quarter. Legal & General Group Plc now owns 770,359 shares of the biopharmaceutical company’s stock worth $433,150,000 after buying an additional 30,778 shares during the period. Banque Cantonale Vaudoise grew its stake in Regeneron Pharmaceuticals by 29.9% in the 3rd quarter. Banque Cantonale Vaudoise now owns 1,500 shares of the biopharmaceutical company’s stock valued at $844,000 after buying an additional 345 shares in the last quarter. Finally, Fieldview Capital Management LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $205,000. 83.31% of the stock is currently owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock worth $4,142,738 in the last 90 days. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $772.03 on Wednesday. The stock has a market cap of $81.62 billion, a P/E ratio of 18.58, a PEG ratio of 2.10 and a beta of 0.41. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $770.79 and its two-hundred day moving average price is $692.02. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $12.07 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a dividend of $0.94 per share. The ex-dividend date was Friday, February 20th. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on REGN. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. Evercore boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, Guggenheim raised their target price on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.